Patents-Review.com
🔗 Permalink
Assignee profile:

argenx BV

City:

Ghent

Country:

Belgium

Published Applications:

21

Last publication date:

2025-10-30

Patent Grants:

21

Last grant date:

2026-03-03

Top Inventors for applications by argenx BV

These are the the leading inventors for applications assigned to argenx BV:

Recent patent applications by argenx BV

argenx BV based in Ghent, BE has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2025-10-30 ✅ Patent 12,565,538 granted on 2026-03-03
US20250333543A1
Chemistry; metallurgy

FCRN/ANTIGEN-BINDING MOLECULES AND METHODS OF USE

 #2 | 2025-04-17 ✅ Patent 12,344,678 granted on 2025-07-01
US20250122310A1
Chemistry; metallurgy

FCRN/HSA BINDING MOLECULES AND METHODS OF USE

 #3 | 2024-01-04 ✅ Patent 12,180,293 granted on 2024-12-31
US20240002523A1
Chemistry; metallurgy

CD70 combination therapy

 #4 | 2022-08-25 ✅ Patent 11,708,403 granted on 2023-07-25
US20220267424A1
Chemistry; metallurgy

Antibodies to human complement factor C2B and methods of use

 #5 | 2022-06-09 ✅ Patent 12,060,413 granted on 2024-08-13
US20220177555A1
Chemistry; metallurgy

Method of preparing pH-dependent antibodies

 #6 | 2022-04-21 ✅ Patent 11,591,386 granted on 2023-02-28
US20220119509A1
Chemistry; metallurgy

Antibodies to human complement C2B

 #7 | 2022-03-10 ✅ Patent 11,827,701 granted on 2023-11-28
US20220073604A1
Chemistry; metallurgy

IL-6 binding molecules

 #8 | 2021-10-28 ✅ Patent 11,713,354 granted on 2023-08-01
US20210332140A1
Chemistry; metallurgy

Galectin-10 antibodies

 #9 | 2020-12-24 ✅ Patent 12,030,949 granted on 2024-07-09
US20200399382A1
Chemistry; metallurgy

Multispecific antibodies against IL-5 and IL-4R

 #10 | 2020-12-24 ✅ Patent 11,591,388 granted on 2023-02-28
US20200399363A1
Chemistry; metallurgy

Pharmaceutical formulations of FcRn inhibitors suitable for subcutaneous administration

 #11 | 2020-07-16 ✅ Patent 11,712,468 granted on 2023-08-01
US20200222532A1
Human necessities

CD70 combination therapy

 #12 | 2020-07-09 ✅ Patent 11,447,544 granted on 2022-09-20
US20200216528A1
Chemistry; metallurgy

Anti-IL-22R antibodies

 #13 | 2020-05-21 ✅ Patent 11,649,295 granted on 2023-05-16
US20200157248A1
Chemistry; metallurgy

Asymmetric multispecific antibodies

 #14 | 2020-05-21 ✅ Patent 11,261,246 granted on 2022-03-01
US20200157207A1
Chemistry; metallurgy

Anti-IL-22R antibodies

 #15 | 2020-01-23 ✅ Patent 12,202,900 granted on 2025-01-21
US20200024344A1
Chemistry; metallurgy

Compositions and methods for treating immune thrombocytopenia

 #16 | 2019-09-05 ✅ Patent 11,434,298 granted on 2022-09-06
US20190270823A1
Chemistry; metallurgy

Antibodies to CD70

 #17 | 2019-08-08 ✅ Patent 11,530,271 granted on 2022-12-20
US20190241668A1
Chemistry; metallurgy

CD70 combination therapy

 #18 | 2019-07-25 ✅ Patent 11,479,879 granted on 2022-10-25
US20190225672A1
Chemistry; metallurgy

Triple vector for expressing antibody molecules in full therapeutic format

 #19 | 2019-07-18 ✅ Patent 12,071,486 granted on 2024-08-27
US20190218310A1
Chemistry; metallurgy

Bispecific antigen binding construct

 #20 | 2019-06-27 ✅ Patent 12,240,875 granted on 2025-03-04
US20190194277A1
Chemistry; metallurgy

Use of FCRN antagonists for treatment of generalized myasthenia gravis

 #21 | 2018-06-28 ✅ Patent 11,505,585 granted on 2022-11-22
US20180179258A1
Chemistry; metallurgy

FcRn antagonists and methods of use

Also check out argenx BV's (Ghent, Belgium) applicant profile with 48 patent applications submitted.

AssigneeID:

358768 ⎘